Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02684058 : Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
PhasePhase 2
AgesMin: 12 Months Max: 17 Years
Eligibility
Inclusion Criteria:

- Diagnosis of BRAF V600 mutant High Grade glioma that has relapsed, progressed or
failed to respond to frontline therapy

- Diagnosis of BRAF V600 mutant Low Grade glioma with progressive disease following
surgical excision, or non-surgical candidates with necessity to begin first systemic
treatment because of a risk of neurological impairment with progression.

- Confirmed measurable disease

Exclusion Criteria:

- Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK
inhibitor

- HGG patient: Cancer treatment within the past 3 weeks. LGG patient: Any systemic
therapy or radiotherapy prior to enrollment

- LGG patients: history of allergic reaction or contraindications to the use of
carboplatin or vincristine

- Stem cell transplant within the past 3 months

- History of heart disease

- Pregnant or lactating females
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02684058      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740